AtheroGenics, a pharmaceutical firm developing drugs for treatment of chronic inflammatory diseases, is raising $175 million through notes that come due in 2012.

The company said the funds would be used in part to support an ongoing clinical trial,other research and development activities, and working capital.

AtheroGenics: www.atherogenics.com